National Innovation Office: consultation procedure

The federal agency for medicines and healthcare products (FAMHP) prepares the implementation of a National Innovation Office in order to promote and facilitate the research and development of new innovative drug products in Belgium. This office will serve as an easy and central access point to the regulatory and scientific expertise of the FAMHP with the final aim to accelerate availability of new and innovative medicinal products to patients. The three key areas on which the Innovation Office would focus for developing future activities in a stepwise approach are: national scientific-technical/regulatory advice services, innovation support in R&D and specific services to support small and medium-sized enterprises (SMEs) and academia.

In this context the FAMHP has developed a questionnaire, in order to fine-tune the FAMHP’s current plans for implementing a National Innovation Office and to align the objectives of the Innovation Office to the current and future needs of SME’s and academia.

The questionnaire can be completed on a voluntary basis and the results will be analysed and presented anonymously to the participating stakeholder groups at a follow-up workshop which will normally be organised at the FAMHP by mid December 2016.

This survey is open to SMEs, academic research centres and affiliated organisations (e.g. academic spin-offs, hospitals, technology transfer offices, etc.). Contributions are also encouraged from individuals, enterprises, authorities and organisations involved in collaborating with SME’s and academic researchers involved in pharmaceutical R&D.

The FAMHP kindly invites the representatives of the different target groups to complete and send back the survey if possible before 31/08/2016 to our mailbox address as explained on page 2 of the questionnaire.


Implementation of the national Innovation Office at FAMHP


Last updated on 16/12/2020